Revisión sistemática sobre el síndrome de Guillain Barré asociado a la COVID-19.

Objective: To analyze the available evidence on the association between COVID-19 and Guillain Barré syndrome. Acquisition of the evidence: A systematic review was held guided by Prism Declaration. We reviewed articles published in English, in Pubmed database, from January to October 2020, referring to the Guillain Barré Syndrome associated with COVID-19. It was included in the preparation of database 50 articles that met the eligibility criteria. Results: Patients over 60 years of age (46.6%) and male sex (63.3%) predominated. 60% of the patients showed the neurological clinic, after the resolution of the symptoms of COVID-19 infection. The latency period between the onsets of COVID-19 and Guillain Barré syndrome, and vice versa, was 12.4 ± 6.3 days. Most patients had typical Barré Guillain Syndrome (76.3%) and the most frequent electrophysiological subtype was acute inflammatory demyelinating polyneuropathy (46.6%). Conclusions: The growing number of cases reported with Guillain Syndrome Barré during the COVID-19 pandemic constitutes the main evidence to point to SARSCOV2 infection as a causal agent. Clinical manifestations, variants and electrophysiological subtypes show no differences with Guillain Syndrome Barré pre-pamdemic. The variability in the temporary relationship between the manifestations of VOCID-19 and the development of Guillain Barré syndrome suggests mechanisms of parainfectious and postinfectious presentation mechanisms. [ABSTRACT FROM AUTHOR]